ARVN
Arvinas Inc
NASDAQ: ARVN · HEALTHCARE · BIOTECHNOLOGY
$8.45
-2.99% today
Updated 2026-09-11
Market cap
$545.20M
P/E ratio
33.80
P/S ratio
1.72x
EPS (TTM)
$0.25
Dividend yield
—
52W range
$7 – $15
Volume
0.7M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
8.0
Growth
A7.5
Quality
B+5.0
Profitability
C+4.7
Valuation
C6/9
Piotroski F-Score
Moderate
-1.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$13.93
+64.85%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy6 Buy7 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 1,015.00% QoQ
+ Debt/equity 0.01x — low leverage
Risks
- Altman Z -1.30 — distress zone
- Thin margins at 2.94%
- Negative free cash flow $-48.50M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $131.40M | $78.50M | $263.40M | $262.60M | $316.70M |
| Net income | $-271.90M | $-367.30M | $-198.90M | $-80.80M | $169.40M |
| EPS | — | — | — | — | $0.25 |
| Free cash flow | $-280.30M | $-350.70M | $-261.10M | $-275.70M | $-48.50M |
| Profit margin | -206.93% | -467.90% | -75.51% | -30.77% | 2.94% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-24 | SMALDONE, ALSUP LAURIE | Buy | 22,714 | — |
| 2026-06-24 | SMALDONE, ALSUP LAURIE | Buy | 15,527 | — |
| 2026-06-24 | SAIK, ANDREW | Sale | 5,696 | $8.16 |
Peer comparison
Smart narrative
Arvinas Inc trades at $8.45. representing a P/E of 33.80x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -1.30, it sits in the distress. TTM revenue stands at $316.70M. with profit margins at 2.94%.
Frequently asked questions
What is Arvinas Inc's stock price?
Arvinas Inc (ARVN) trades at $8.45, on a P/E of 33.8x and a P/S of 1.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Arvinas Inc overvalued?
Arvinas Inc carries a Smart Value Score of 56/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Arvinas Inc (ARVN)?
The 12-month analyst consensus target is $13.93, about 64.9% above the current $8.45. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Arvinas Inc's revenue?
Arvinas Inc's trailing twelve-month revenue is $316.70M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Arvinas Inc's Altman Z-Score is -1.30, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.72x
ROE1.65%
Beta1.76
50D MA$8.71
200D MA$10.49
Shares out0.06B
Float0.06B
Short ratio—
Avg volume0.7M
Performance
1 week-10.01%
1 month-5.80%
3 months+12.82%
YTD-28.75%
1 year—
3 years—
5 years—